Migraine is a debilitating neurologic disorder that occurs in about 17% of women and 6% of men in the United States. It affects all aspects of life—from work and school attendance and performance to family life, leisure time, personal relationships, and finances. Unfortunately, migraine is often underdiagnosed and undertreated. This program will review the symptoms of and diagnostic criteria for migraine, appropriate use of traditional therapies, and the role of new and emerging therapies in the management of patients with episodic and chronic migraine.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Identify patients with migraine based on symptomatology and diagnostic criteria
- Implement evidence-based strategies for the treatment and prevention of episodic and chronic migraine
- Utilize efficacy and safety evidence to identify the appropriate role of new and emerging therapies for patients with migraine
NPs and PAs
CNE Credit Designation Statement
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.00, which are eligible for 1.00 pharmacology credits.
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
AAPA Credit Designation Statement
In support of improving patient care, this activity has been planned and implemented by Continuing Education Alliance and Boston University. Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until August 30, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA Planner: Lawrence Herman, PA-C, MPA, University of Texas Medical Branch – Galveston
This activity was developed from a series of programs cosupported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech; Novartis Pharmaceuticals Corporation; Sanofi US and Regeneron Pharmaceuticals; Shire; and Teva.
This activity is supported by an educational grant from Teva.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Hindiyeh: speaker: Amgen, Lilly.
Dr Tiso has no relevant financial relationships to disclose.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Carmela A. Townsend, DNP, MS/MBA, RN, Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; Lawrence Herman, MPA, PA-C of the University of Texas Medical Branch, Galveston, Texas; and Ruth Cohen, and Craig Borders of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 31, 2019
Expiration date: August 30, 2020
Any internet connected computer or mobile device with any of the following browsers:
Internet Explorer, Google Chrome, Mozilla Firefox, Safari
© 2020 Practicing Clinicians Exchange. All Rights Reserved. CPCE95119-7D